Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dutch Delegation Promises ‘Seamless’ Transition To EMA’s New Home

Executive Summary

Dutch officials took part in the December meeting of the EMA management board and presented details of their plans for the agency’s relocation to Amsterdam. The board also adopted the 2018 work program and budget, which allow for a 6.8% rise in fee-related revenue next year, and said phase 2 of the Brexit business continuity plan would begin in January.

You may also be interested in...



Dutch Defend Choice Of Amsterdam For EMA As Italy Tries To Shift Agency To Milan

The Italian government has asked the Court of Justice of the EU to annul the decision to site the European Medicines Agency in Amsterdam and wants to move the agency instead to Milan. But the Dutch government insists that the selection process was “fair” and that the need for temporary premises had been made clear all along.

Industry Response To Brexit Survey Key For Future Planning, Says EMA

Sponsors of centrally authorized medicines in the EU are being urged to respond to a survey by the European Medicines Agency aimed at gauging industry's preparedness for Brexit. Companies have until Feb. 9 to complete survey, which the EMA says is critical to help with resource planning and ensuring a smooth transition.

EMA To Consult Staff On Relocation Plans Again As Brexit Time Pressure Mounts

The EMA is planning another survey to see how many of its staff are likely to follow it to Amsterdam, while the agency’s executive director says having to move into temporary premises while a permanent home is constructed is inconvenient but should allow core regulatory activities to be pursued.

Related Content

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel